|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.29 USD | +1.79% |
|
-3.97% | +28.50% |
| Feb. 25 | Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… |  |
| Feb. 24 | Vaxcyte, Inc., Q4 2025 Earnings Call, Feb 24, 2026 |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 9 | |||||||
| 15 | |||||||
| 18 | |||||||
| 19 | |||||||
| 19 | |||||||
| 23 | |||||||
| 14 | |||||||
| 21 | |||||||
| 13 | |||||||
| 17 | |||||||
| 18 | |||||||
| 14 | |||||||
| - | - | - | 1 | ||||
| 4 | |||||||
| 11 | |||||||
| 7 | |||||||
| 17 | |||||||
| 15 | |||||||
| 18 | |||||||
| 5 | |||||||
| Average | 14 | |||||||
| Weighted average by Cap. | 16 |
- Stock Market
- Equities
- PCVX Stock
- Sector Vaxcyte, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
